Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Phenylglycine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC known ✓ | P12931 | 1/20 | 0.54 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.50 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.50 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.50 |
| ▸ | DPP4 known ✓ | P27487 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | GRM8 | O00222 | 1/20 | 0.50 |
| ▸ | GRM6 | O15303 | 1/20 | 0.50 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.50 |
| ▸ | F2 | P00734 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenylglycine SCHEMBL540378 | 1.00 | CYP2D6 (0.54) | CYP2D6SRCLMNAMAPK1HSD17B10 | |
| Phenylglycine SCHEMBL6718142 | 1.00 | CYP2D6 (0.54) | CYP2D6SRCLMNAMAPK1HSD17B10 | |
| Phenylglycine SCHEMBL2003211 | 1.00 | CYP2D6 (0.54) | CYP2D6SRCLMNAMAPK1HSD17B10 | |
| Phenylglycine SCHEMBL4431879 | 1.00 | CYP2D6 (0.54) | CYP2D6SRCLMNAMAPK1HSD17B10 | |
| Phenylglycine SCHEMBL157180 | 0.97 | CYP2D6 (0.56) | CYP2D6SRCLMNAMAPK1HSD17B10 | |
| Phenylglycine SCHEMBL30559595 | 0.97 | CYP2D6 (0.56) | CYP2D6SRCLMNAMAPK1HSD17B10 | |
| Phenylglycine SCHEMBL159420 | 0.97 | CYP2D6 (0.56) | CYP2D6SRCLMNAMAPK1HSD17B10 | |
| Phenylglycine SCHEMBL27801493 | 0.97 | CYP2D6 (0.56) | CYP2D6SRCLMNAMAPK1HSD17B10 | |
| Phenylglycine SCHEMBL31402004 | 0.97 | CYP2D6 (0.56) | CYP2D6SRCLMNAMAPK1HSD17B10 | |
| Phenylglycine SCHEMBL11576917 | 0.97 | CYP2D6 (0.56) | CYP2D6SRCLMNAMAPK1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 230 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117480161-A | Novel 2, 3-dihydro-1H-pyrrolo [3,2-b ] pyridine derivatives as sigma ligands | 塔拉森调理公司 | 2024-01-30 | — | — | CN | disclosed |
| CN-116887917-A | Catalyst and application thereof | 周学明 | 2023-10-13 | — | — | CN | disclosed |
| US-20230271961-A1 | Pan-Tropic Entry Inhibitors | UNIV EMORY (US) | 2023-08-31 | — | — | US | disclosed |
| US-11649235-B2 | Pan-tropic entry inhibitors | EMORY UNIVERSITY (US) | 2023-05-16 | — | — | US | disclosed |
| WO-2022179557-A1 | CATALYST AND APPLICATION THEREOF | 周学明 | 2022-09-01 | — | — | WO | disclosed |
| US-11254702-B2 | Thionyl tetrafluoride modified compounds and uses | THE SCRIPPS RESEARCH INSTITUTE (US) | 2022-02-22 | — | — | US | disclosed |
| US-20210017178-A1 | Pan-Tropic Entry nhibitors | UNIV EMORY (US) | 2021-01-21 | — | — | US | disclosed |
| EP-3548465-A1 | THIONYL TETRAFLUORIDE MODIFIED COMPOUNDS AND USES | The Scripps Research Institute (US) | 2019-10-09 | — | — | EP | disclosed |
| US-20190284226-A1 | THIONYL TETRAFLUORIDE MODIFIED COMPOUNDS AND USES | THE SCRIPPS RESEARCH INSTITUTE | 2019-09-19 | — | — | US | disclosed |
| EP-2499127-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-09-05 | — | — | EP | disclosed |
| US-20040254160-A1 | Benzothiazepine derivatives | ELOBIX AB (SE) | 2004-12-16 | — | — | US | disclosed |
| US-20040157827-A1 | 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents | PEVARELLO PAOLO (IT) | 2004-08-12 | — | — | US | disclosed |
| US-20040067933-A1 | Chemical compounds | ELOBIX AB (SE) | 2004-04-08 | — | — | US | disclosed |
| US-6695977-B2 | LIQUID CRYSTALLINE MIXTURE | BASF AKTIENGESELLSCHAFT (DE) | 2004-02-24 | — | — | US | disclosed |
| US-20030187040-A1 | 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents | PHARMACIA & UPJOHN SPA (IT) | 2003-10-02 | — | — | US | disclosed |
| US-20030066984-A1 | Use of chiral, uncharged metal compounds as dopants for liquid-crystalline materials | BASF AKTIENGESELLSCHAFT (DE) | 2003-04-10 | — | — | US | disclosed |
| EP-1124811-A1 | 2-UREIDO-THIAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS | PHARMACIA & UPJOHN S.p.A. (IT) | 2001-08-22 | — | — | EP | disclosed |
| WO-2000026203-A1 | 2-UREIDO-THIAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS | PHARMACIA & UPJOHN S.P.A. (IT) | 2000-05-11 | — | — | WO | disclosed |
| US-5998611-A | Process for producing cephem compounds in an aqueous medium | EISAI CHEMICAL CO., LTD. (JP) | 1999-12-07 | — | — | US | disclosed |
| EP-0832893-A1 | Process for the production of cephem compounds | EISAI CHEMICAL CO., LTD. (JP) | 1998-04-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11649235-B2 | Pan-tropic entry inhibitors | CXCR4, CCR5, CXCL12 | SRC 941/4885SLC6A2 564/4885SLC6A4 661/4885 |
| US-20040067933-A1 | Chemical compounds | SLC10A2, SLC10A1, ABCB11 | SRC 1541/4885SLC6A2 166/4885SLC6A4 303/4885 |
| US-20210017178-A1 | Pan-Tropic Entry nhibitors | CXCR4, CXCL12, CCR5 | SRC 1806/4885SLC6A2 865/4885SLC6A4 994/4885 |
| US-20190284226-A1 | THIONYL TETRAFLUORIDE MODIFIED COMPOUNDS AND USES | SFXN3, TST, SIRT3 | SRC 703/4885SLC6A2 507/4885SLC6A4 723/4885 |
| US-20030187040-A1 | 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents | UCK2, ULK3, CDK2 | SRC 618/4885SLC6A2 4273/4885SLC6A4 4335/4885 |
| US-20230271961-A1 | Pan-Tropic Entry Inhibitors | CXCR4, CCR5, CXCL12 | SRC 971/4885SLC6A2 653/4885SLC6A4 890/4885 |
| US-20040157827-A1 | 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents | UCK2, ULK3, CDK2 | SRC 618/4885SLC6A2 4273/4885SLC6A4 4335/4885 |
| US-20040254160-A1 | Benzothiazepine derivatives | SLC10A2, SLC10A1, ABCB11 | SRC 2645/4885SLC6A2 64/4885SLC6A4 120/4885 |
| US-11254702-B2 | Thionyl tetrafluoride modified compounds and uses | SFXN3, TST, SIRT3 | SRC 703/4885SLC6A2 507/4885SLC6A4 723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.